Helixmith Co., Ltd.

This early-stage study tested the safety of a new gene-based injection called Engensis in people with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder. Twelve adult participants received injections into their weakened leg muscles over 270 days. The main goal …

This study tested whether injections of an experimental drug called VM202 (Engensis) into the calf muscle could help people with severe blockages in their leg arteries, a condition called critical limb ischemia. The goal was to see if the drug could safely promote new blood vesse…

This early-stage study tested the safety of a new gene therapy called VM202 (Engensis). It was injected directly into the heart muscle of nine patients during their coronary artery bypass surgery, specifically in areas that could not be fully repaired by the surgery itself. The m…

This small study tested whether injections of an experimental drug called Engensis are safe for people with ALS (Lou Gehrig's disease). Eighteen participants received either the drug or a placebo injection into their muscles over several months. Researchers primarily checked for …

This early-stage study tested the safety of a new gene therapy called VM202 (Engensis) in 12 people with critical limb ischemia, a severe form of poor leg circulation causing pain and ulcers. The goal was to see if injections into the leg muscle were safe and if they might improv…

This early-stage study aimed to check if an experimental injection called VM202 is safe for people with ALS (Lou Gehrig's disease). It involved 18 adults recently diagnosed with ALS to see what side effects might occur. The main goal was to understand safety, not to prove if the …

This study followed 8 people with ALS (amyotrophic lateral sclerosis) for an extra 6 months to check the long-term safety of an experimental drug called Engensis. All participants had already received the drug or a placebo in a previous trial. The main goal was to monitor for any…

This study tested whether a new treatment called VM202 could safely reduce pain caused by nerve damage from diabetes. Over 500 adults with painful diabetic neuropathy received either the VM202 injection or a placebo shot in their legs. Researchers measured changes in daily pain l…

This early-stage study tested the safety of a new gene therapy called Engensis (VM202) for people with painful nerve damage caused by diabetes. Twelve participants received injections in their leg muscles to see if the treatment was safe and if it could reduce their chronic pain.…

This study tested whether a new gene therapy called Engensis (VM202) could safely reduce pain in people with diabetic nerve damage in their legs. Over 100 adults with long-term, painful diabetic neuropathy participated. They received either the experimental injections or a placeb…

This study tested whether a drug called Engensis, given as injections into the calf muscles, could safely reduce pain in the feet and lower legs of people with diabetic neuropathy. 162 participants were randomly assigned to receive either the real drug or a placebo (dummy) inject…

This study followed 101 people for one year to check the long-term safety and see if pain relief lasted from a prior trial of Engensis, an experimental injection for painful diabetic nerve damage. Participants had previously received either the real treatment or a placebo shot in…

This was a 6-month follow-up study to see if the pain relief from an experimental gene therapy called Engensis lasted over time. It involved 106 people with painful diabetic nerve damage who had already completed the main treatment study. The goal was to check if the reduction in…